VolitionRx
Singapore, Singapore· Est.
VolitionRx delivers early‑diagnostic blood tests using nucleosome epigenetics for oncology, sepsis and related diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $2.2M
AI Company Overview
VolitionRx delivers early‑diagnostic blood tests using nucleosome epigenetics for oncology, sepsis and related diseases.
OncologySepsisInflammation
Technology Platform
Nucleosomics™ quantifies disease‑specific epigenetic alterations on circulating nucleosomes; Capture‑Seq™ isolates ultra‑pure circulating tumor DNA for liquid‑biopsy applications.
Opportunities
Expansion into routine cancer screening, FDA clearance for NETosis assay, and service contracts with pharma for drug development.
Risk Factors
Regulatory approval timelines, competition from mutation‑based liquid biopsies, and need for large‑scale clinical validation.
Competitive Landscape
Differentiates from Guardant, GRAIL, and Illumina by focusing on epigenetic nucleosome markers rather than DNA mutations, offering potentially higher sensitivity for early disease.